Pharmaceutical service outsourcing big "cake" global growth rate of 16%

The world has suffered a financial crisis and the international pharmaceutical service outsourcing industry has shown a "blowout" market. On June 22nd, at the Second China International Service Outsourcing Cooperation Conference on International Cooperation in Pharmaceutical R&D and Innovation, the famous pharmaceutical contracting companies from the United States, Canada, the United Kingdom, India and other countries met with nearly 100 medical pick-up companies in the province. Investigate and explore international cooperation in pharmaceutical R&D and innovation.

Statistics show that the total value of the global biopharmaceutical R&D outsourcing market has reached US$28 billion and is growing at an annual rate of 16%. It is expected that it will reach US$36 billion by 2010, of which the Chinese market for baggage will grow fastest in the world. Experts revealed that pharmaceutical companies around the world are almost facing the issue of expiring drug patents, and they must increase their research and development efforts. However, due to shortage of funds, they will outsource research and development. If you outsource locally, you can save 20%, and if you send out packages to China, you can save 50-60%. Therefore, China's offshore pharmaceutical outsourcing is ushering in a new spring. Not long ago, the Ph.D. team headed by Zhu Chengxian, an American-Chinese Chinese, set up a new company in Nanjing High-tech Zone, and soon received a single-sample medical outsourcing data outsourcing business of more than RMB 1 million in the United States.

Shyam, CEO of SzyfCo Pharmaceuticals, Canada, said that his company specializes in anti-hepatocarcinal drug R&D. When they choose to pick up companies, China is second only to the Western countries. This not only reduces costs, but also because Chinese medicine has strong research and development capabilities. “The Canadian market is limited. Cooperation with Chinese companies and our company has expanded its territory.”

Although international pharmaceutical outsourcing "cake" is tempting, there are still many "shortcomings" for Chinese companies. According to Gong Bangqiang, chief scientist of Canadian Biosynergwutical Biotech Co., Ltd., a French company wants to outsource the experiment of 500 monkeys and has visited many cities in China, but so far it has not been able to find those who meet the criteria. He reminded, “Chinese companies must pick up international pharmaceutical outsourcing business and must enhance their own quality.” Their company has started to build a corresponding organization in Wuxi, starting with high standards, the goal is to obtain the United States FDA and other certification, to undertake high-end pharmaceutical outsourcing business.

The quality of enterprises is not mainly about how many beautiful workshops are built, how many advanced facilities there are, and there are several doctors. Chen Hong, director of international affairs at U.S. Technology and Technology Group, pointed out that what is important is software and philosophy. She said that there are many pharmaceutical companies in China, but the only ones that are professionally certified by the United States and the European Union are the key misconceptions. We should emphasize the authenticity, integrity, reliability, and originality. The regulations are closer. The hardware requirements are often not high. “Our company’s senior expert, who has done GMP certification in the basement of his own home, has obtained initial approval,” she explained by way of example.

To cut medical outsourcing "cakes" more, there are still many "don't tell the truth." Zhang Quanda, chief scientist of the American Biomol company, proposed several suggestions to the provincial enterprises: The company must have "celebrity", that is, people who have influence in the industry, so that it is convenient to accept orders; the requirements of the contractor must be well understood and "He hurts together"; strives to possess technology that no one else has; it does not suddenly ask the contractor to ask for business to fail; often communicates with the contracting party and informs the progress of the project. In addition, outsourcing of medical services is inseparable from the quality of service. Zhang Fangliang, president of Kingsley, which specializes in pharmaceutical outsourcing services, said that his company has set up its R&D center in New Jersey, USA, and selected its production base in Nanjing. The direct effect of this is to facilitate communication and provide value-added services. "The outsourcing of pharmaceutical outsourcing companies depends on their brains, not simply completing the customer's list."